EGFR and cancer: Signaling through the plasma membrane epidermal growth factor receptor (EGFR, pmEGFR) and mitochondrial EGFR (mtEGFR) is often overactivated in cancer, and EGF‐activated pmEGFR has been reported to increase FASN activity, and consequently de novo palmitate synthesis in prostate and breast cancer cell lines (pC3 and MDA‐MB‐231 cells, respectively).